

FIG. 1




FIG. 2

Local TPS $\geq 50\%$ (n = 58; 43%)					Local TPS 1 - 49% (n = 77; 57%)				
	Atez (N=28)	Tira + Atez (N=29)	All Pis (N=58)			Atez (N=39)	Tira + Atez (N=38)	All Pis (N=77)	
Age (yr)					Age (yr)				
Median	65	69	65.5		Median	69	68	68	
Min - Max	40 - 83	49 - 84	40 - 84		Min - Max	44 - 83	44 - 82	42 - 83	
Sex					Sex				
Male	21 (72.4%)	15 (51.7%)	36 (62.1%)		Male	27 (69.2%)	24 (63.2%)	51 (66.2%)	
Female	8 (27.6%)	14 (48.3%)	22 (37.9%)		Female	12 (30.8%)	14 (36.8%)	26 (33.8%)	
Race					Race				
Asian	9 (31.0%)	9 (31.0%)	18 (31.0%)		Asian	14 (35.9%)	9 (23.7%)	23 (29.9%)	
White	18 (62.1%)	18 (62.1%)	36 (62.1%)		White	22 (56.4%)	24 (63.2%)	46 (59.7%)	
Multiple	0 (0%)	0 (0%)	0 (0%)		Multiple	1 (2.6%)	0	1 (1.3%)	
Unknown	2 (6.9%)	2 (6.9%)	4 (6.9%)		Unknown	2 (5.1%)	5 (13.2%)	7 (9.1%)	
ECOG at screening					ECOG at screening				
0	7 (24.1%)	11 (37.9%)	18 (31.0%)		0	7 (17.9%)	12 (31.6%)	19 (24.7%)	
1	22 (75.9%)	18 (62.1%)	40 (69.0%)		1	32 (82.1%)	26 (68.4%)	58 (75.3%)	
Tobacco History					Tobacco History				
N	2 (6.9%)	3 (10.3%)	5 (8.6%)		N	5 (12.8%)	4 (10.5%)	9 (11.7%)	
Y	27 (93.1%)	26 (89.7%)	53 (91.4%)		Y	34 (87.2%)	34 (89.5%)	68 (88.3%)	
Tumor Histology					Tumor Histology				
Non-Squamous	20 (69.0%)	21 (72.4%)	41 (70.7%)		Non-Squamous	20 (51.3%)	19 (50.0%)	39 (50.6%)	
Squamous	9 (31.0%)	8 (27.6%)	17 (29.3%)		Squamous	19 (48.7%)	19 (50.0%)	38 (49.4%)	

FIG. 3

Local TPS ≥ 50%			Local TPS 1 - 49%		
	Atezo (N=29)	Tira + Atezo (N=29)	All PIs (N=58)		
On Study	22 (75.9%)	26 (89.7%)	48 (82.8%)	On Study	
Continuing Treatment	14 (48.3%)	22 (75.9%)	36 (62.1%)	Continuing Treatment	
Discontinued Treatment	8 (27.6%)	4 (13.8%)	12 (20.7%)	Discontinued Treatment	
Adverse event	1 (3.4%)	1 (3.4%)	2 (3.4%)	Adverse event	
Physician decision	1 (3.4%)	0	1 (1.7%)	Physician decision	
Radiographic PD	5 (17.2%)	2 (6.9%)	7 (12.1%)	Radiographic PD	
Other	1 (3.4%)	1 (3.4%)	2 (3.4%)	Symptomatic deterioration	
Discontinued study	7 (24.1%)	3 (10.3%)	10 (17.2%)	Discontinued study	
Death	6 (20.7%)	2 (6.9%)	8 (13.8%)	Death	
Withdrawal by subject	1 (3.4%)	1 (3.4%)	2 (3.4%)	Withdrawal by subject	

FIG. 4

	ITT: Local TPS ≥ 1%		Local TPS ≥ 50%		Local TPS 1 - 49%	
	Alezo (N=63)	Tira + Alezo (N=64)	Alezo (N=27)	Tira + Alezo (N=27)	Alezo (N=36)	Tira + Alezo (N=37)
Responders (n)	10	20	5	14	5	6
BOR % (95% CI)	15.9 (6.06 to 25.69)	31.3 (19.11 to 43.39)	18.5 (2.01 to 35.02)	51.9 (31.15 to 72.55)	13.9 (1.20 to 26.57)	16.2 (2.99 to 29.44)
Difference in BOR % (95% CI, p-value)	15.38 (-0.70 to 31.46, 0.0536)		33.33 (5.76 to 60.91, 0.0164)		2.33 (-16.80 to 21.46, 0.9079)	
CR	2 (3.2%)	0	1 (3.7%)	0	1 (2.8%)	0
PR	8 (12.7%)	20 (31.3%)	4 (14.8%)	14 (51.9%)	4 (11.1%)	6 (16.2%)
SD	34 (54.0%)	28 (43.8%)	15 (55.6%)	10 (37.0%)	19 (52.8%)	18 (48.6%)
PD	19 (30.2%)	16 (25.0%)	7 (25.9%)	3 (11.1%)	12 (33.3%)	13 (35.1%)

FIG. 5





FIG. 6



		Atez (N=58)	Tifa + Atez (N=57)
Treatment-related AE			
Any		38 (55.9%)	51 (76.1%)
Serious		7 (10.3%)	7 (10.4%)
Grade 3-5		10 (14.7%)	9 (13.4%)
Led to discontinuation		4 (5.9%)	3 (4.5%)
Immune-related AE*			
Any		23 (33.8%)	35 (52.2%)
Rash		7 (10.3%)	20 (29.9%)
Hepatitis (diagnosis and lab)		10 (14.7%)	6 (9.0%)
IR R		1 (1.5%)	11 (16.4%)
Hypothyroidism		4 (5.9%)	3 (4.5%)
Pancreatitis (diagnosis and lab)		2 (2.9%)	5 (7.5%)
Hyperthyroidism		2 (2.9%)	2 (3.0%)
Colitis		1 (1.5%)	1 (1.5%)
Diabetes Mellitus		1 (1.5%)	1 (1.5%)
Pneumonitis		1 (1.5%)	1 (1.5%)
Ocular Inflammatory Toxicity		1 (1.5%)	1 (1.5%)
Myocarditis		1 (1.5%)	0
Nephritis		0	1 (1.5%)

FIG. 7

FIG. 8A




FIG. 8B

Baseline Risk Factors	Total	n	n	Response (%)	n	Response (%)	Response (%)	ORs	95% CI	Placebo + Atezolizumab	Traglumab + Atezolizumab
43 Patients	135	66	11	16.2	67	21	31.2	2.37	(1.04, 5.41)	Placebo + Atezolizumab	Traglumab + Atezolizumab
HistoGeneX IHC CLONE SP283 membrane staining intensity											
<1%	17	10	1	10.0	7	0	NE	<0.01	(0.00, >99.99)		
1-49%	53	26	5	21.4	20	3	15.0	0.55	(0.12, 2.40)		
≥50%	13	20	4	20.0	15	4	26.7	4.23	(1.13, 16.04)		
NA	52	10	0	NE	12	0	41.7	>99.99	(0.00, NE)		
HistoGeneX IHC CLONE SP263 percent infiltrating immune cells											
<1%	17	10	0	NE	10	1	10.0	>99.99	(0.00, >99.99)		
1-49%	53	26	4	21.8	19	5	26.3	1.92	(0.33, 10.54)		
≥50%	13	20	4	30.8	16	3	18.8	0.50	(0.10, 2.52)		
NA	52	10	0	NE	12	0	41.7	>99.99	(0.00, NE)		
HistoGeneX IHC CLONE SP263 percent infiltrating immune cells											
<1%	17	10	2	20.0	7	4	57.1	1.75	(0.29, 10.54)		
1-49%	53	26	8	30.8	23	11	47.8	1.80	(0.57, 4.94)		
≥50%	13	20	3	23.1	17	3	17.6	0.67	(0.10, 4.07)		
NA	52	10	0	NE	12	0	41.7	>99.99	(0.00, NE)		
HistoGeneX IHC CLONE SP263 percent infiltrating immune cells											
<1%	17	10	0	NE	6	0	0.0	>99.99	(0.00, NE)		
1-49%	53	26	3	23.1	17	3	17.6	0.67	(0.10, 4.07)		
≥50%	13	20	3	23.1	17	3	17.6	0.67	(0.10, 4.07)		
NA	52	10	0	NE	12	0	41.7	>99.99	(0.00, NE)		
Spring TIGIT IHC (Ventana)											
<1%	16	10	0	NE	6	0	0.0	>99.99	(0.00, NE)		
1-49%	29	15	3	20.0	12	2	16.7	1.50	(0.37, 5.31)		
≥50%	30	13	2	15.4	17	2	11.8	0.73	(0.07, 8.04)		
NA	30	13	2	15.4	17	2	11.8	0.73	(0.07, 8.04)		
Spring TIGIT IHC (Ventana)											
<1%	16	10	0	NE	6	0	0.0	>99.99	(0.00, NE)		
1-49%	29	15	3	20.0	12	2	16.7	1.50	(0.37, 5.31)		
≥50%	30	13	2	15.4	17	2	11.8	0.73	(0.07, 8.04)		
NA	30	13	2	15.4	17	2	11.8	0.73	(0.07, 8.04)		
C-reactive protein (Covance)											
< 3 mg/L	21	11	2	18.2	10	3	30.0	1.93	(0.33, 10.54)		
≥ 3 mg/L	116	54	9	11.7	27	16	40.7	2.22	(0.80, 5.41)		
NA	8	3	0	NE	5	0	0.0	>99.99	(0.00, NE)		
Lactate dehydrogenase											
< 0.3	98	49	2	12.3	50	12	24.0	1.89	(0.84, 3.31)		
≥ 0.3	36	19	4	21.1	17	5	29.4	4.22	(0.98, 18.12)		
NA	1	0	0	NE	0	0	NE	>99.99	(0.00, NE)		
Tobacco history											
Yes	14	7	2	28.6	7	0	NE	<0.01	(0.00, >99.99)		
No	121	63	6	12.8	45	21	46.8	3.11	(1.20, 7.95)		

FIG. 9A

	Placebo + alezolizumab (n = 68)	Tiragolumab + alezolizumab (n = 67)
ORR	16.2% (11 responders)	31.3% (21 responders)
Difference in ORR (95% CI)	15.17% (-0.46%, 30.79%)	
Stratified odds ratio (95% CI)	2.57 (1.07, 6.14)	

FIG. 9B

PD-L1 IHC 22C3 TPS ≥ 50%

	Placebo + atezolizumab (n = 29)	Tiragolumab + atezolizumab (n = 29)
ORR	17.2% (5 responders)	55.2% (16 responders)
Difference in ORR (95% CI)	37.93% (11.75%, 64.11%)	
Unstratified odds ratio (95% CI)	5.91 (1.76, 19.81)	

PD-L1 IHC 22C3 TPS 1 - 49%

	Placebo + atezolizumab (n = 39)	Tiragolumab + atezolizumab (n = 38)
ORR	15.4% (6 responders)	13.2% (5 responders)
Difference in ORR (95% CI)	-2.23% (-20.44%, 15.98%)	
Unstratified odds ratio (95% CI)	0.83 (0.23, 3.00)	

FIG. 10A




FIG. 10B




FIG. 11A





FIG. 11B

	Placebo + Atezo (n = 29)	Tira + Atezo (n = 29)
Patients with event (%)	20 (69.0%)	10 (34.5%)
Median (months) (95% CI)	3.88 (2.07, 4.73)	NE (5.42, NE)
Unstratified HR (95% CI)	0.33 (0.15, 0.72)	



Patients remaining at risk
Placebo + Atezolizumab (N=29)
Tirapolumab + Atezolizumab (N=29)
Only deaths for which a complete date is available are considered events.

FIG. 11C




FIG. 12A




FIG. 12B




FIG. 13B




FIG. 13C




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D




FIG. 16




FIG. 17




FIG. 18

